Jan 23, 2023 7:00am EST Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
Jan 12, 2023 7:00am EST Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids
Nov 02, 2022 4:02pm EDT Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
Oct 27, 2022 7:00am EDT Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022
Oct 21, 2022 7:48am EDT Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
Oct 21, 2022 7:00am EDT Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
Oct 19, 2022 7:10am EDT Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
Oct 12, 2022 7:00am EDT Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
